# US 2016/0250200 A1 · Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250200 A1
- Document ID: US20160250200A1
- Status: Published application
- Kind: A1
- Application number: 14/935,246
- Filed: 2015-11-06
- Published: 2016-09-01
- Earliest claimed: 2003-01-16
- Assignees: ACADIA Pharmaceuticals Inc.
- Applicants: ACADIA Pharmaceuticals Inc.
- Inventors: David M. Weiner; Robert E. Davis; Mark R. Brann; Carl-Magnus A. Andersson; Allan K. Uldam
- Web page: https://patentgrep.com/patent/US20160250200A1

## CPC

- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 59/255: Tartaric acid
- C07D 211/58: attached in position 4
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

## Claims

### Claim at position 1

1-86. (canceled)

### Claim 87

A method for treating hallucinations or delusions comprising administering to a patient a therapeutically effective amount of a compound of Formula (I) or a salt thereof:

### Claim 88 (depends on 87)

The method of claim 87, wherein the hallucinations or delusions are associated with Parkinson's disease psychosis.

### Claim 89 (depends on 87)

The method of claim 87, wherein the patient has Parkinson's disease psychosis.

### Claim 90 (depends on 87)

The method of claim 87, wherein the method is for treating hallucinations in the patient.

### Claim 91 (depends on 87)

The method of claim 87, wherein the method is for treating delusions in the patient.

### Claim 92 (depends on 87)

The method of claim 87, wherein a tartrate salt of the compound of Formula (I) is administered to the patient.

### Claim 93 (depends on 92)

The method of claim 92, wherein the tartrate salt of the compound of Formula (I) in an amount of about 0.001 mg to about 50 mg is administered to the patient.

### Claim 94 (depends on 92)

The method of claim 92, wherein the tartrate salt of the compound of Formula (I) in an amount of about 15 mg is administered to the patient.

### Claim 95 (depends on 92)

The method of claim 92, wherein the tartrate salt of the compound of Formula (I) in an amount of about 25 mg is administered to the patient.

### Claim 96 (depends on 92)

The method of claim 92, wherein the tartrate salt of the compound of Formula (I) in an amount of about 50 mg is administered to the patient.

### Claim 97 (depends on 92)

The method of claim 92, wherein the tartrate salt of the compound of Formula (I) is administered daily.

### Claim 98 (depends on 92)

The method of claim 92, wherein the tartrate salt of compound of Formula (I) is administered once daily.

### Claim 99 (depends on 92)

The method of claim 92, wherein the tartrate salt of compound of Formula (I) is administered two times daily.

### Claim 100 (depends on 92)

The method of claim 92, wherein the tartrate salt of compound of Formula (I) is formulated for oral administration as a unit dose.

### Claim 101 (depends on 100)

The method of claim 100, wherein the unit dose is a tablet.

### Claim 102 (depends on 87)

The method of claim 87, wherein the therapeutically effective amount of the compound of Formula (I) or a salt thereof is from 0.01 mg/kg of body weight per day to 100 mg/kg of body weight per day.
